anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The clinical trial study is designed as a prospective, multicenter, single-group target-value clinical study with single-armed target value. Subjects are patients with moderate-severe or greater (MR ≥ 3+) FMR who have received adequate treatment but are still symptomatic. The safety and efficacy of the investigational product and its performance are evaluated using the above clinical trial primary endpoint and secondary endpoint indicators. All subjects in this study will be followed up at 30 days, 3 months, 6 months, and 12 months after device implantation, and clinical data obtained will be analyzed and summarized, and clinical reports will be used for submission for product registration. The study will continue to follow up subjects for 2-5 years after surgery to observe the occurrence of adverse events and to make an accurate and credible evaluation of the long-term safety and efficacy of this investigational product. All relevant clinical data will be collected, organized and statistically analyzed by an independent data management and statistics center and clinical monitoring organization. The core laboratory assesses the relevant imaging data during the clinical trial, and the CEC (Clinical Event Committee) is specially established to determine the endpoint events of the clinical trial. The clinical study consists of two phases: the first phase is a feasibility (FIM) clinical trial and the second phase is a confirmatory clinical trial; the sample size of the FIM clinical trial is not included in the second phase.
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition and a health food, produced by the prevention of Mengen reaction occurring at the time of taking a saponin-containing galenical such as medicinal carrot and by a process for increasing the absorptivity of a crude drug (a method for causing a chicken egg protein to absorb an active constituent of the galenical).  <P>SOLUTION: The effect of saponin, being an effective component of a galenical, against many clinical states (tumor prevention, physiology, etc.) is confirmed and reported. While this invention enhances the systemic absorption of an active element and suppresses adverse effects, it is intended that the vital function is heightened more quickly to further heighten the beneficial effect of galenical saponin and so that the efficacy which has been seeked for a long time and the prevention and treatment of cancer tumor, etc., can be anticipated. The pharmaceutical composition and the health food are characterized so that a living body affinity component is selected and adsorbed by a chicken egg protein near to a human protein composition and so that the protein is easily and conveniently taken in.  <P>COPYRIGHT: (C)2011,JPO&INPIT
To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women. We will also explore whether suppression of ovarian hormones in pre-menopausal women (using leuprolide acetate) impairs BAT activity.
Peptides for conjoint use in therapy of patients having an infection caused by HPV 16 or a like human papillomavirus, or in which such an HPV has been implicated, especially cervical dysplasias said peptides being from 15 to 24 amino acids long and consisting of or including the following sequences of amino acids of human papillomavirus (HPV) 16 L1 protein: (1) SEQ ID. NO: 1 = as residues 311-325, or a conservatively modified variant thereof; (2) SEQ ID. NO: 2 = as residues 321-335, or a conservatively modified variant thereof; and (3) SEQ. ID. NO: 3 = as residues 331-345, or a conservatively modified variant thereof. Compositions of these three peptides per se or for use in such therapy are included in the invention.
FIELD: medicine. SUBSTANCE: method involves administering immunoglobulin preparations with additionally applied Karavayev Vitaon balsam administered in the form of 1 drop introduced into the entrance to the mouth or by treating the oral cavity mucosa with cotton wool tampon wetted with the balsam at least 3 times a day before giving food. Beside that, the Vitaon balsam is clockwise applied to abdominal skin in circular movements until full absorption takes place. The Vitaon balsam is also applied to the sphincter any region and to the macerated regions of buttocks skin after each defecation action. EFFECT: accelerated treatment; no contraindications. 24 cl, 3 tbl
An enriched hydrolyzable tannin blend derived from  Phyllanthus amarus  is provided. An optimized aqueous extraction method for  Phyllanthus amarus  is provided to maximize the levels of bioactive hydrolyzable tannins including corilagin, geraniin, nirurin and other low molecular weight hydrolyzable tannoids. The method produces a  Phyllanthus amarus  extract containing a hydrolyzable tannin blend as an amorphous dry powder. In an embodiment, the  Phyllanthus amarus  extract contains 7-13% by weight corilagin, 3.5-10% nirurin, 1-2% geraniin, and 9-20% low molecular weight hydrolyzable tannoids. In another embodiment, the  Phyllanthus amarus  extract contains 12-20% geraniin and 12-20% low molecular weight hydrolyzable tannoids. Potential uses of said enriched hydrolyzable tannin compositions for hepatoprotection in a human subject are described herein.
A water-free super-sticky type adhering film for whitening teeth comprises three layers of structures. A first layer is a transparent or non-transparent soft film sticky adhering layer adhered to the teeth. A second layer is a water-free super-sticky whitening layer tightly adhered to the first layer. A third layer is a peeled backing layer. The water-free super-sticky whitening layer is formed by the steps of dissolving high-viscosity polymer and tooth whitening materials in a volatile solution and then stoving the volatile solution at the temperature of 60 DEG C to 80 DEG C, wherein the manufacture is implemented according to eight optimized formulas. The water-free super-sticky type adhering film for whitening the teeth has the advantages that the adhesive force to the teeth is strong, the adhesive time is long, a water-free super-sticky whitening agent in the adhering film can fully exert on the teeth, and the adhering film greatly improves the tooth whitening effect and is comfortable and convenient to use.
A method and device for managing establishment of a communications link between an external instrument (EI) and an implantable medical device (IMD) are provided. The method stores, in a memory in at least one of the IMD or the EI, a base scanning schedule that defines a pattern for scanning windows over a scanning state. The method enters the scanning state during which a receiver scans for advertisement notices during the scanning windows. At least a portion of the scanning windows are grouped in a first segment of the scanning state. The method stores, in the memory, a scan reset pattern for restarting the scanning state. Further, the method automatically restarts the scanning state based on the scan reset pattern to form a pseudo-scanning schedule that differs from the base scanning schedule and establishes a communication session between the IMD and the EI.
Circular RNAs (circRNAs) have emerged as pivotal regulators of gene expression and cellular processes in various physiological and pathological conditions. In recent years, there has been a growing interest in investigating the role of circRNAs in inflammatory lung diseases, owing to their potential to modulate inflammation-associated pathways and contribute to disease pathogenesis. Inflammatory lung diseases, like asthma, chronic obstructive pulmonary disease (COPD), and COVID-19, pose significant global health challenges. The dysregulation of inflammatory responses demonstrates a pivotal function in advancing these diseases. CircRNAs have been identified as important players in regulating inflammation by functioning as miRNA sponges, engaging with RNA-binding proteins, and participating in intricate ceRNA networks. These interactions enable circRNAs to regulate the manifestation of key inflammatory genes and signaling pathways. Furthermore, emerging evidence suggests that specific circRNAs are differentially expressed in response to inflammatory stimuli and exhibit distinct patterns in various lung diseases. Their involvement in immune cell activation, cytokine production, and tissue remodeling processes underscores their possible capabilities as therapeutic targets and diagnostic biomarkers. Harnessing the knowledge of circRNA-mediated regulation in inflammatory lung diseases could lead to the development of innovative strategies for disease management and intervention. This review summarizes the current understanding of the role of circRNAs in inflammatory lung diseases, focusing on their regulatory mechanisms and functional implications.
This study has a mixed between- and within-subject design. Participants are young adults (aged 18-45) with ADHD and non-ADHD matched controls. They will be recruited from locations around the community, consented, screened for eligibility, then scheduled for 2 study days. Study days will be at least 48 hours apart. Thus, there will be a total of 3 lab visits across a 3 week period. Participants will be administered study drug on one study day and placebo on the other study day. They will complete a battery of cognitive/behavioral tasks and answer questionnaires on both study days.
Two-year carcinogenesis studies were conducted in rats and mice. Positive findings were observed in both species. Rats were treated at intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days and 10 mg/rat/15 days. 

These doses correspond to 0.9-, 1.5-, and 3-fold (in females) and 0.8-, 0.8-, and 2-fold (in males) the systemic exposure [AUC0-30 days] achieved in women receiving the recommended dose of 500 mg/month. An increased incidence of benign ovarian granulosa cell tumors and testicular Leydig cell tumors was evident, in females dosed at 10 mg/rat/15 days and males dosed at 15 mg/rat/30 days, respectively. Mice were treated at oral doses of 0, 20, 150 and 500 mg/kg/day. These doses correspond to 0-, 0.8-, 8.4- and 18-fold (in females) and 0.8-, 7.1- and 11.9-fold (in males), the systemic exposure (AUC0-30 days) achieved in women receiving the recommended dose of 500 mg/month. There was an increased incidence of sex cord stromal tumors (both benign and malignant) in the ovary of mice at doses of 150 and 500 mg/kg/day. Induction of such tumors is consistent with the pharmacology-related endocrine feedback alterations in gonadotropin levels caused by an antiestrogen. 

Fulvestrant was not mutagenic or clastogenic in multiple in vitro tests with and without the addition of a mammalian liver metabolic activation factor (bacterial mutation assay in strains of Salmonella typhimurium and Escherichia coli, in vitro cytogenetics study in human lymphocytes, mammalian cell mutation assay in mouse lymphoma cells and in vivo micronucleus test in rat). 

In female rats, fulvestrant administered at doses ≥0.01 mg/kg/day (0.6% the human recommended dose based on body surface area [BSA in mg/m2]), for 2 weeks prior to and for 1 week following mating, caused a reduction in fertility and embryonic survival. No adverse effects on female fertility and embryonic survival were evident in female animals dosed at 0.001 mg/kg/day (0.06% the human dose based on BSA in mg/m2). Restoration of female fertility to values similar to controls was evident following a 29-day withdrawal period after dosing at 2 mg/kg/day (equivalent to the human dose based on BSA in mg/m2). The effects of fulvestrant on the fertility of female rats appear to be consistent with its antiestrogenic activity. The potential effects of fulvestrant on the fertility of male animals were not studied, but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days fulvestrant showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides. Changes in the testes and epididymides had not recovered 20 weeks after cessation of dosing. These fulvestrant doses correspond to 1.3-, 1.2-, and 3.5-fold the systemic exposure [AUC0-30 days] achieved in women receiving the recommended dose of 500 mg/month.
An early adolescent girl presented to the emergency department (ED) of her local hospital following a syncopal episode after a warm bath on a background of increasing breathlessness for 1-year duration. On examination, she was fully alert, no pain or injuries from her syncope, she was warm and well perfused, her respiratory rate at rest was normal and she showed no signs of respiratory distress, there were no signs of seizure activity such as incontinence or tongue biting, she had a raised Jugular Venous Pressure (JVP), a loud pansystolic murmur, there was no cyanosis and no oedema. She was referred for a chest radiograph due to her history of breathlessness and for an ECG based on the examination findings of a murmur. Her ECG showed marked right axis deviation with tall T waves in V1 and P waves in lead II. Therefore, she was referred for an outpatient echocardiogram which demonstrated severely dilated right ventricular (RV) with impaired RV function. She was diagnosed with primary pulmonary hypertension.Her history included red flag symptoms including worsening breathlessness and syncope. Syncopal episodes are common and mostly benign, that is, vasovagal, but attention to a detailed history including constitutional symptoms and examination is crucial to ensure appropriate investigations and management. While causes are commonly benign in paediatrics, it is important to ensure that there are no features of an underlying cause. This includes ruling out commonly seen paediatric presentations that could present as an unwitnessed syncopal episode and this should include seizures, anaemia, arrhythmias, hypotension, hypoglycaemia and pain. If other causes are not ruled out, it can lead to an incorrect diagnosis as found in this patient when she presented a further three times to ED while waiting for her tertiary appointment.
The invention belongs to the medical field, and specifically, relates to a novel glycyrrhetinic acid-modified lipid, a liver targeting liposome, a micelle and a compound, and their preparation method. The novel glycyrrhetinic acid-modified lipid contains glycyrrhetinic acid as a liver targeting mediating material, and is utilized as a membrane material of a liposome or a micelle to enable the liposome or the micelle to have liver targeting activity. Specifically, the novel glycyrrhetinic acid-modified lipid is prepared from raw materials of glycyrrhetinic acid and a phosphatide or cholesterol by a reaction in a condensing agent-containing solvent. The invention also provides a liver targeting liposome carrier and a liver targeting micelle carrier mediated by glycyrrhetinic acid. The liver targeting liposome carrier is prepared from the novel glycyrrhetinic acid-modified lipid, cholesterol and a phosphatide. The liver targeting micelle carrier is prepared directly from the novel glycyrrhetinic acid-modified lipid. The invention also provides a liver targeting liposome compound or a liver targeting micelle compound comprising an encapsulation layer of the liver targeting liposome carrier and the liver targeting micelle carrier. Therefore, glycyrrhetinic acid mediation-related drugs can be targeted to hepatic cells; toxicity of the glycyrrhetinic acid mediation-related drugs on normal tissue is reduced; and drug effects of prevention and treatment of liver complaints are improved.
Vanishing lung syndrome (VLS) or idiopathic giant bullous disease is a rare condition characterized by giant emphysematous bullae, classically presenting as a slowly enlarging bulla that compresses normal lung parenchyma and causes mediastinal shift, leading to increasing dyspnea and reduced exercise tolerance. Intermittent sudden worsening of symptoms may be seen because of secondary pneumothorax due to rupture of these bullae. Here we present three cases of vanishing lung syndrome in children due to tuberculosis (TB). Reports on VLS due to TB are bare minimum. In contrast to most of the published case reports, our cases had a moderate to rapid progression, bilateral extensive bullae and isoniazid which has been traditionally thought to be the causative factor was not used in one of our patients. All three are female patients arising new horizons of research regarding whether there is any sex predominance.
Damage to renal tubular epithelial cells (RTECs) signaled the onset and progression of sepsis-associated acute kidney injury (SA-AKI). Recent research on mitochondria has revealed that mitophagy plays a crucial physiological role in alleviating injury to RTECs and it is suppressed progressively by the inflammation response in SA-AKI. However, the mechanism by which inflammation influences mitophagy remains poorly understood. We examined how macrophage migration inhibitory factor (MIF), a pro-inflammatory protein, influences the PINK1-Parkin pathway of mitophagy by studying protein-protein interactions when MIF was inhibited or overexpressed. Surprisingly, elevated levels of MIF were found to directly bind to PINK1, disrupting its interaction with Parkin. This interference hindered the recruitment of Parkin to mitochondria and impeded the initiation of mitophagy. Furthermore, this outcome led to significant apoptosis of RTECs, which could, however, be reversed by an MIF inhibitor ISO-1 and/or a new mitophagy activator T0467. These findings highlight the detrimental impact of MIF on renal damage through its disruption of the interaction between PINK1 and Parkin, and the therapeutic potential of ISO-1 and T0467 in mitigating SA-AKI. This study offers a fresh perspective on treating SA-AKI by targeting MIF and mitophagy.
BACKGROUND: Sepsis can lead to myocardial depression, playing a significant role in sepsis pathophysiology, clinical care, and outcome. To gain more insight into the pathophysiology of the myocardial response in sepsis, we investigated the expression of microRNA in myocardial autopsy specimens in critically ill deceased with sepsis and non-septic controls.
MATERIALS AND METHODS: In this retrospective observational study, we obtained myocardial tissue samples collected during autopsy from adult patients deceased with sepsis (n = 15) for routine histological examination. We obtained control myocardial tissue specimens (n = 15) from medicolegal autopsies of cadavers whose cause of death was injury or who were found dead at home and the cause of death was coronary artery disease with sudden cardiac arrest. RNA was isolated from formalin-fixed paraffin- embedded (FFPE) cardiac samples using the RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Invitrogen). Differentially expressed miRNAs were identified using edgeR v3.32. MicroRNA was considered up- or down-regulated if the false discovery rate was < 0.05 and logarithmic fold change (log2FC) ≥ 1 for up-regulated or log2FC ≤ -1 for down-regulated miRNAs. The mean difference and 95% confidence interval (CI) were calculated for normalized read counts. Predicted miRNA targets were retrieved using Ingenuity Pathway Analysis (IPA) software, and pathway enrichment and classification were performed using PantherDB. For miRNA - mRNA interaction analysis, differentially expressed genes were analyzed by 3`mRNA sequencing.
RESULTS: Differential expression analysis identified a total of 32 miRNAs in the myocardial specimens. Eight miRNAs had a significant change in the mean difference based on the 95% CI, with the largest increase in mean counts in septic samples with hsa-miR-12136 and the highest fold change with hsa-miR-146b-5p. The threshold for down-regulated miRNAs in sepsis compared to controls was obtained with hsa-miR-144-5p and hsa-miR-451a, with the latter having the largest decrease in mean counts and fold decrease. The miRNA - mRNA interaction analysis identified eight miRNAs with target genes also differentially expressed in septic hearts. The highest number of potential targets were identified for hsa-miR-363-3p.
CONCLUSIONS: Several regulatory miRNAs were up-or down-regulated in the myocardial tissue of patients deceased with sepsis compared to non-septic subjects. The predicted target genes of miRNAs and miRNA-mRNA interaction analysis are associated with biological functions related to cardiovascular functions, cell viability, cell adhesion, and regulation of inflammatory and immune response.
PURPOSE:To provide a cosmetic having a combination of excellent lipoperoxide production-inhibitory activity, SOD-like activity, collagen synthesis-promotive activity and restoring activity for dermatic injuries due to ultraviolet irradiation, each for human skin, capable of preventing skin aging and of maintaining youthful, healthy skin. CONSTITUTION:The objective cosmetic having the above-mentioned advantages can be obtained by formulating (I) 100 pts.wt. of a cosmetic base such as a makeup cosmetic, hair cosmetic, or bathing agent with (II) as the essential ingredient, 0.0005-5.0 (pref. 0.005-1.0) pts.wt., on a solid basis, of a decomposition product obtained by treating an alkali extract of rice, etc., with at least two kinds of enzymes, pref. (A) actinase and (B) at least one kind of protease selected from pepsins, trypsins, papains, peptidases and bromelain (esp. pepsin and trypsin). This cosmetic, because of bearing the above-mentioned advantages, have the following additional advantages: (1) normalizing human skin turnover; (2) preventing skin spots, etc., through reducing variations in the areas among keratinous cells; and (3) activating the skin and reducing fine wrinkles.
FIELD: medicine, in particular, narcology; may be used for treatment and prophylaxis of alcohol addiction, abstinent and alcohol withdrawal syndrome. SUBSTANCE: agent contains three components in homeopathically balanced potencies. 100 g of agent includes 1.0 g of mixture of equal parts of potentiated solutions in 45-deg alcohol: acetic acid, 30c; sodium sulfate, 39c; hydrochloride methoclopramide, 36c; 1.0 g of 70-deg alcohol; 98.0 g of sugar granules. For treatment of alcohol addiction, agent is administered by 7-9 granules 3 times a day before or during meals. After 7-day administration of agent, interval for 1-3 days takes place. EFFECT: improved efficiency; reduced treatment time of alcoholism of various severity. 3 cl, 3 ex
Pulse pressure variation will be recorded via an arterial catheter after anesthetic induction, before pneumoperitoneum, after pneumoperitoneum, before infusion of 6% hydroxyethyl starch, and after infusion of 6% hydroxyethyl starch. Stroke volume will be also measured to differentiate the fluid responders.
The invention relates to anexternally used preparation for recurrent diseases which are mainly caused by herpesvirus and other coronavirus. The invention also is suitable for secondary various pathogenesis infections, such as candidiasis and gonotoxin, or other secondary virus infection caused by other pathogenesis infection. The invention also provides the preparation process. The preparation can be conveniently used on human skin, mucosa-infective positions such as mouth, nasal cavity, vaginal and anal opening. The essential raw material for said preparation is plant and animal material, so it is safe and can protect host cell and probiotics. It takes many components, and possesses synergic effect, which overcomes shortcoming of bad suitability for mutant virus of single component.